The Significance of Cytokine Expression. Anaplastic Large Cell Lymphoma

Similar documents
Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU

Immunopathology of Lymphoma

Classification of Hematologic Malignancies. Patricia Aoun MD MPH

GENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute

Primary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders

Andrea s SI Session PCB Practice Test Test 3

Case Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent

T cell lymphoma diagnostics and differential diagnosis to Hodgkin lymphoma

Overview B cell development T cell development

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Corrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

During past decades, because of the lack of knowledge

HAEMATOLOGICAL MALIGNANCY

Chapter 4 Cellular Oncogenes ~ 4.6 -

Gastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

Two Cases of Primary Gastric Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT)-type

Anaplastic Large Cell Lymphoma (of T cell lineage)

Extramedullary precursor T-lymphoblastic transformation of CML at presentation

Methods used to diagnose lymphomas

ECP meeting, Lisbon, september 2012 Slide seminar New and old challenges in the diagnosis of peripheral T-cell lymphomas

Pathology of Hematopoietic and Lymphoid tissue

Antigen Presentation and T Lymphocyte Activation. Shiv Pillai MD, PhD Massachusetts General Hospital Harvard Medical School. FOCiS

5/1/13. The proportion of thymus that produces T cells decreases with age. The cellular organization of the thymus

Differential cytokine expression in EBV positive peripheral T cell lymphomas. Title. Ho, JWY; Liang, RHS; Srivastava, G

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

Incidence. Bimodal age incidence 15-40, >55 years Childhood form (0-14) more common in developing countries M:F=1.5:1; in all subtypes except NS

The Adaptive Immune Response. T-cells

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

High-Grade B-cell Lymphoma Double Hit or Double Expressing

Case 3. Ann T. Moriarty,MD

The Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D.

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

Pathology of Hematopoietic and Lymphoid tissue

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells

Lymphatic System Disorders

Defined lymphoma entities in the current WHO classification

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies

Examples of questions for Cellular Immunology/Cellular Biology and Immunology

Contents. vii. Preface... Acknowledgments... v xiii

Immune response. This overview figure summarizes simply how our body responds to foreign molecules that enter to it.

Low grade High grade , immune suppression chronic persistent inflammation viruses B-symptoms

T cell development October 28, Dan Stetson

LYMPHOMAS an overview of some subtypes of NHLs

The development of T cells in the thymus

1. Overview of Adaptive Immunity

88-year-old Female with Lymphadenopathy. Faizi Ali, MD

Follicular Lymphoma. ced3 APOPTOSIS. *In the nematode Caenorhabditis elegans 131 of the organism's 1031 cells die during development.

Diagnosis of lymphoid neoplasms has been

Supplementary Figure 1. Example of gating strategy

SH/EAHP WORKSHOP 2017 CASE 210 PRESENTATION

Molecular Diagnosis. Nucleic acid based testing in Oncology

Nucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis

Hepatic Lymphoma Diagnosis An Algorithmic Approach

BIT 120. Copy of Cancer/HIV Lecture

Meeting Report. From December 8 to 11, 2012 at Atlanta, GA, U.S.A

Supplementary Figure 1 IL-27 IL

Neoplastic proliferation arising from white blood cells. Introductory remarks. Classification

Effector T Cells and

Workshop Case # 8 (H 4205/07)

Ig light chain rearrangement: Rescue pathway

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information

Aggressive B-Cell Lymphomas

Defensive mechanisms include :

Mixed Phenotype Acute Leukemias

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells

Lymphoma and Pseudolymphoma

Tolerance 2. Regulatory T cells; why tolerance fails. FOCiS. Lecture outline. Regulatory T cells. Regulatory T cells: functions and clinical relevance

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

The development of clonality testing for lymphomas in the Bristol Genetics Laboratory. Dr Paula Waits Bristol Genetics Laboratory

Adaptive immune responses: T cell-mediated immunity

Eurekah Bioscience Collection

NEW ENTITIES IN AGGRESSIVE B CELL LYMPHOMA. Joon Seong Park, M.D. Dept. of Hematology-Oncology Ajou University School of Medicine

Development of B and T lymphocytes

WBCs Disorders 1. Dr. Nabila Hamdi MD, PhD

CD30 expression utilization for the accuracy of classical Hodgkin s lymphoma staging

Lymphocytoma Cutis. Cynthia M. Magro MD. Director of Dermatopathology Weill Medical College of Cornell University New York, New York

Chapter 22: The Lymphatic System and Immunity

Reactive and Neoplastic Lymphocytosis

Acute myeloid leukemia. M. Kaźmierczak 2016

Tolerance 2. Regulatory T cells; why tolerance fails. Abul K. Abbas UCSF. FOCiS

COURSE: Medical Microbiology, MBIM 650/720 - Fall TOPIC: Antigen Processing, MHC Restriction, & Role of Thymus Lecture 12

Foundations in Microbiology

Innate immunity (rapid response) Dendritic cell. Macrophage. Natural killer cell. Complement protein. Neutrophil

Plasma cell myeloma (multiple myeloma)

Malignant lymphomas are neoplasms that arise from B

Cover Page. The handle holds various files of this Leiden University dissertation.

Introduction to Immunology Part 2 September 30, Dan Stetson

Cytotoxic T Cells in HIV and Other Retroviral Infections

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features

T Cell Development. Xuefang Cao, MD, PhD. November 3, 2015

Leukaemia Section Short Communication

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline

Page 4: Antigens: Self-Antigens The body has a vast number of its own antigens called self-antigens. These normally do not trigger immune responses.

Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation

TCR, MHC and coreceptors

Transcription:

Med. J. Kagoshima Univ., Vol. 47, Suppl. 2. 39-42, November, 1995 Invited Lecture The Significance of Cytokine Expression in Hodgkin's Disease and Anaplastic Large Cell Lymphoma FELLER, A.C., and MERZ, H. Deparment for Pathology, Medical University of Liibeck, Liibeck, Germany Cytokines are known to be involved in cellular proliferation and differentiation. Under the influence of these growth factors, cells having the equivalent receptor are driven into various differentiations forms from immature precursors to functional endstage cells. The cytokine network is a well balanced system, within which the different peptides can act in a hormone-like manner, in paracrine pathways as well as with autocrine mechanisms. It is known that some clinical symptomes of reactive as well as of neoplastic diseases are due to an imbalance of a cytokine expression. Such factors may thus also influence the microenvironment in some neoplastic diseases. It is well documented that the eosinophilia in Hodgkin's disease is due to a secretion of IL-5 produced by the Hodgkin cells themselves1. The influenceof tumor growth by cytokines has been shown for plasmocytomas. The neoplastic cell growth can be induced by IL-6 either in a paracrine or autocrine pathway. In that cases IL-6 can be produced by either the neoplastic cell clone or by stromal cells. The specificity of the IL-6 effect can be demonstrated by blocking the tumor cell growth by specific anti-il-6 antibodies3. The morphology of some malignant lymphomas in terms of cellular constituents or growth pattern clearly give indications for an interaction between neoplastic and non-neoplastic cell compartments. Some entities are characterized by a specific milieu of bystander cells (Hodgkin's disease) or a distinct growth pattern (e. g. centroblastic centrocytic lymphoma, T-zone lympho ma, T-cell lymphoma of AILD-type, anaplastic large cell lymphoma)4,5. Semiquantitative analysis of cytokine RNA of malignant lymphomas strongly indicates in some cases a deregulation of the cytokine expression. About one third of the cases show a strong overexpression of Address for Corresspondence:Fellen AC. lnsttute of Pathology, Medical Uninersity of Liibeck, Ratzeburger Alice 160, D-23538 Liibeck, Germany. various cytokines at the Northern blot level, indicating an abundant quantity of these factors which are obviously produced by the tumor cells6, 7' 8. It must be additionally kept in mind that cytokines physiologically act at extremely low concentrations. However, the expression in malignant lymphomas is completely unpredictable which means that a distinct lymphoma entity does not exhibit a distinct cytokine profile. A recently described T cell growth factor - interleukin 99-has been shown to have the typical pleiotropic effect on different cell lineages. Among these effects IL-9 simulates the proliferation of mature T cells. Clonally amplified T cells survive in vitro under the influence of exogenous 11-9 indefinitely. Interestingly, IL-9 expression is within the lymphoid cell system restricted to stimulated peripheral T lymphocytes and to the lymphoma entites anaplastic large cell lymphoma and Hodgkin's disease by means of Northern blot analysis (table 1) as well as by PCR. Other B - and T cell lymphomas are negative. Table 1. Cytokine expression in Hodgkin's disease (HD), anaplastic large cell lymphoma (LCAL) and lymphoblastoid cell lines (LBC). Different cytokines are expressed in the different lymphoma types. IL-9 expression is restricted to these three entities. n IL-2 IL-4 IL-6 IL-7 IL-9 IL-10 HD (16) 3 11 7/7 7 8 LCAL( 8) 1 5 n.d. 4 n.d. LBC ( 5) 2 5 5 5 4 5 Within the mouse system IL-9-dependent CD4- positive T cells can be transfected with recombinant IL- 9 cdna which results in an autocrine production of IL- 9 and an independent clonal T-cell growth. The injection of these transfected T-cell clones into mice results in the development of a malignant lymphoma in all animals. Non-transfected exogeneous IL-9-dependent T-cell clones never induced a tumor growth when

Med. J. Kagoshima Univ., Vol. 47, Suppl. 2, November, 1995 [40] * j. 9,10 injected into mice The morphological investigation of the animal tumors revealed after injection into the peritoneal cavity the spread of a malignant lymphoma. All animals showed a lymph node enlargement in the abdomen. The subcutaneous application of the IL-9 autocrine Tcell clones resulted in evolvement of skin tumors. Morphologically the tumors constituted from large bizarre anaplastic cells, some of which strongly resembled Hodgkin or Sternberg-Reed cells. Some tumors showed a cohesive growth pattern and were accompanied by an eosinophilia (fig.1-3). Moreover, early involvement of lymph nodes exhibited an intrasinusoidal growth pattern. The tumor infitrates showed a diffuse fibrosis of the lymphnode tissue. The immunophenotypic data revealed an expression of CD4 and CD25 on the tumor cells. The T cell receptor B- chain gene showed a clonal rearrangement pattern. Fig.3. Intrasinusoidal growth pattern of murine anaplastic large cell lymphoma (upper and lower left). Table 2. Comparison of morphological immunophenotypic and genotypic data between the mouse tumor evolving from autocrine mouse T-cells and human anaplastic large cell lymphoma expressing IL-9 and IL-9-receptors. IL-9 mouse LCAL human TcR,? rec. IL-2R? CD71 CD30 eosinophilia Hodgkin cells intrasinusoidal tumor T-zone infiltration fibrosis Fig.l. A comparison between Hodgkin's disease, lympho cyte depletion compared to the anaplastic mouse tumor (right side) showing large bizarre blasts resembling Hodgkin and Sternberg-Reed cells. Additionally a cohesive growth pattern is visible. tumor growth -: In table 2 the many similarities between human anaplastic large cell lymphomas expressing IL-9 and mouse T-cell lymphoma having 11-9 as an autocrine growth factor are given. Thus, it seems possible that IL9 is involved in tumor proliferation and even in transformational events in human anaplastic large cell lymphoma. This is underlined by the observation that IL-9-RNA can be detected in Hodgkin and SternbergReed cells in Hodgkin's disease by in situ hybridization Recently we were able to detect the translocation t (2;5) in cases of Hodgkin's disease '', which, so far, was thought to be restricted to cases of anaplastic large cell lymphoma. This observation seems especially interest ing under the aspect that the Il-9-gene is now described in its chromosomal location, the gene is located on the long arm of chromosome 5q32-q35. The translocation involves a locus on the long arm of chromosome at 5q35'~. Thus, it might be possible that the chromosom * ^ --m,-* :yt Fig.2. High power view of the mouse tumor cells with large anaplastic cells. al translocation is causing directly or indirectly via inducing transcription factors which might lead to a deregulation of IL-9 gene expression. However, it seems highly probable that not only a

The Significance of Cytokine Expression [41] single cytokine or cytokine receptor is involved in tumor proliferation or transformational events but a variety of these ligands and their receptors may be of influence. In vitro experiments as well as in vivo studies indicate that the cytokine secretion is increased after cell stimulation. This is best known from PHA stimulated peripheral blood T lymphocytes. B cells however do not show an equivalent variety of cytokine expression after in vitro stimulation. EBV infection of B cells on the other hand leads to an over expression of activation antigens on the cell surface. It has been shown that EBV-genome and protein can frequently be detected in some lymphoma types of B and T-cell orign including Hodgkin's disease and anaplastic large cell lymphoma which clearly show signs of cellular activation13. This observation raises the question on the significance of this EBV infection. The relevance is still unclear as most lymphoma entities which have been shown to carry EBV have detectable EBV genomes in only about 20 to 50% of the cases. The in vitro prototype of EBV infected cells are the lymphoblastoid cells from which cell lines can easily be established from patients with EBV positive lympho mas or even from peripheral blood of normal human individuals having passed an EBV infection. We have recently studied lymphoblastoid cell lines (EBV-infected B cells) in order to investigate the cellular events under the condition of longterm cell culture. In principle three major observations can be made: 1. The phenotype of the cells is variable over a time period with an increase of CD30 expression. In part also a CD15 expression is detectable. 2. The number of chromosomal abnormalities during a culture period of several months increases. Moreov er an involvement of the long arm of chromosome 6 was observed, an abnormality which is frequently detected in Hodgkin's disease14. 3. Lymphoblastoid B-cell lines express a number of cytokines at least on the level of mrna which have been thought so far to be either T-cell derived factors or be produced only by stroma cells. This latter observation is of importance, as even a maximal antigenic stimulation of peripheral blood B lymphocytes is never able to induce such an amount of cytokine expression. Thus, this expression is due to the EBV-infection. These experiments may give some more indications for the involvement of cytokines in some lymphoma types. The induction of cytokine expression or even overexpression induces cellular proliferation. The variety of cytokines may be able to act on different cell lineages, e.g. T cells, B cells, monocytes/histiocytes. An increasing and continuing cellular proliferation also increases the number of chromosomal aberrations which finally may lead to autonomous growth (table 3). Table 3. A hypothetic scheme showing the possible involvement of EBV in lymphoma genesis. EBV infection leads to an increse of cytokine expression which may act on different cellular lineages or may even infect different lymphoid cells. These phenomena are paralleled by an increase of chromosomal aberrations. A de crease of EBV expression at the proteine level is possible. EBV M LCL< Cytokines REFERENCES EBV-Infection HD LCAL 1) Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodg kin's disease with eosinophilia. Blood 1990; 75: 13-6. 2) Barlogie BB, Pestling J, Alexanian R. Plasma cell myeloma. New biological insights and advances in therapy. Blood 1989; 73: 865-79. 3) Van Snick J. Interleukin-6: An Overview. Ann Rev Immunol 1990; 8: 253-78. 4) Agnarsson BA, Kadin ME. Ki-1 positive large cell lymphoma. A morphologic and immunologic study of 19 cases. Am J Surg Pathol 1988; 12: 264-74. 5) Suchi T, Lennert K, Tu LY, Kikuchi M, Sato E, Stansfeld AG, Feller AC. Histopathology and immunohistochemistry of peripheral T cell lympho mas: a proposal for their classification. J Clin Pathol 1987; 40: 995-1015. 6) Merz H, Fliedner A, Lehrnbecher T, Sebald W, Miiller-Hermelink HK, Feller AC. Cytokine ex pression in B-cell non-hodgkin lymphomas. Hematol Oncol 1990; 8: 355-61. 7) Merz H, Houssiau FA, Orscheschek K et al. lnterleukin-9 expression in human malignant lym phomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 1991; 78: 1311-17. 8) Jiicker M, Abts H, W. Li et al. Expression of interleukin 6 and lnterleukin 6 Receptor in Hodg kin's disease. Blood 1991; 77: 2413-18. 9) Uyttenhove C, Druez C, Renauls JC, Herin M, Noel H, van Snick J. Autonomous growth and tumorigenicity induced by P40/IL-9 cdna express ion in a mouse P40-dependent T cell line. J Exp

[42) Med. J. Kagoshima Univ., Vol. 47, Suppl. 2, November, 1995 Med 1988; 85: 6934-38. 10) Feller AC, Merz H, Orscheschek K, van Snick J. Cytokine Expression and its possible Involvement in Lymphoma Induction and Progression. In: Racz P, Letvin NL, Gluckman JC (eds): Cytotoxic T Cells in HIV and Other Retroviral Infections. Basel, Karger, 1992; 150-61. 11) Orscheschek K, Merz H, Hell J, Binder T, Bartels H, Feller AC. Large-cell anaplastic lymphomaspecific translocation (t[2;5][p23;q35]) in Hodg kin's disease: indication of a common pathogene sis? Lancet 1995; 345:87-90. 12) Mock BA, Krall M, Kozak CA, Nesbitt MN, Wesley O, McBride W, Renauld JC, van Snick J. IL-9 maps to mouse chromosome 13 and human chromosome 5. Immunogenetics 1990; 31: 265-70. 13) Anagnostopoulos I, Herbst H, Niedobitek G, Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined southern blot and in situ hybridization. Blood 1989; 74: 810-16. 14) Fonatsch C, Diehl V, Schaadt M, Burrichter H, Kirchner HH. Cytogenetic investigations in Hodg kin's disease: Involvement of specific chromosomes in marker formation. Cancer Genet Cytogenet 1986; 20: 39-52.